Crystalline forms of psilacetin
Crystalline forms of 4-acetoxy-N,N-dimethyltryptamine (psilacetin), compositions containing that crystalline form, and their methods of use are disclosed. The crystalline forms of 4-acetoxy-N,N-dimethyltryptamine (psilacetin) according to the disclosure include crystalline 4-acetoxy-N,N-dimethyltryptammonium hydrofumarate, the fumarate salt of psilacetin, and/or crystalline bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate, and pharmaceutical compositions containing a crystalline form of psilacetin.
1. Crystalline bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate.
2. Crystalline bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate according to claim 1 characterized by:
a triclinic, P1 crystal system space group at a temperature of about 200 K,
unit cell dimensions a=8.3965 (13) Å, b=8.9879 (14) Å, c=12.0126 (16) Å, α=101.730 (5)°, β=100.818 (5)°, and γ=112.463 (5)° at a temperature of about 200 K;
an x-ray powder diffraction pattern substantially similar to FIG. 8 ; or
an x-ray powder diffraction pattern characterized by peaks at 7.9, 18.4 and 24.0°2θ±0.2°2θ.
3. A composition comprising crystalline bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate according to claim 1 and an excipient.
4. A composition comprising as crystalline bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate and a second component selected from (a) a purified psilocybin derivative, (b) one or two purified cannabinoids and (c) a purified terpene.
5. Bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate.
6. A method of preventing or treating a psychological disorder comprising the step of:
administering to a subject in need thereof a therapeutically effective amount of crystalline bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate according to claim 1 .
7. A method of preventing or treating a psychological disorder comprising the step of:
administering to a subject in need thereof a therapeutically effective amount of crystalline bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate according to claim 2 .
8. A method of preventing or treating a psychological disorder comprising the step of:
administering to a subject in need thereof a composition according to claim 3 .
9. A method of preventing or treating inflammation and/or pain comprising the step of:
administering to a subject in need thereof a therapeutically effective amount of crystalline bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate according to claim 1 .
10. A method of preventing or treating inflammation and/or pain comprising the step of:
administering to a subject in need thereof a therapeutically effective amount of crystalline bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate according to claim 2 .
11. A method of preventing or treating inflammation and/or pain comprising the step of:
administering to a subject in need thereof a composition according to claim 3 .